Radioimmunotherapy of prostate cancer Journal Article
| Author: | Smith-Jones, P. M. |
| Article Title: | Radioimmunotherapy of prostate cancer |
| Abstract: | In recent years, advances in the rational design of radio-pharmaceuticals have helped in the introduction of clinically useful therapeutic agents into the clinic. in particular radiolabeled monoclonal antibodies such as 90Yibritumomab and 131I-tositumomab have shown to be clinically successful. More recently, 177Lu has emerged as an attractive radionuclide for use in systemic radiotherapy. Like 131I, it has a longer half-live than 90Y which is more suitable to the pharmacokinetics of monoclonal antibodies, but its chemistry is similar to 90Y and, when internalized, it is retained by the tumor whereas 131I can be quickly released. Metastatic prostate cancer is an attractive target for radioimmunotherapy since the cornerstone of current therapy is hormonal therapy, which is only palliative. Prostate cancer is also known to metastasize to areas such as the lymph nodes and bone marrow, sites that are readily accessible to circulating monoclonal antibodies. This review will look at recent advances to the treatment of metastatic prostate cancer with radiolabeled antibodies with a specific emphasis on 177Lu-huJ591, a labeled monoclonal antibody currently under clinical evaluation. |
| Keywords: | cancer survival; treatment outcome; survival rate; unclassified drug; clinical trial; review; nonhuman; bone metastasis; paclitaxel; radiation dose; nuclear magnetic resonance imaging; methodology; radiopharmaceuticals; antigen expression; cell death; unindexed drug; protein targeting; drug structure; radiation response; docetaxel; monoclonal antibody; prostate cancer; prostatic neoplasms; survival time; capromab pendetide in 111; monoclonal antibody j591; antibodies, monoclonal; iodine 131; drug distribution; isotope labeling; vascular endothelium; dosimetry; prostate tumor; radiopharmaceutical agent; metastasis potential; radioisotope; drug half life; tumor growth; radioimmunotherapy; radioisotopes; antibody affinity; dissociation constant; bone marrow metastasis; pentetic acid; yttrium 90; monoclonal antibody b.72.3; rhenium 188; lutetium 177; copper 67; gadoteric acid; humans; human; male; monoclonal antibody 7e11; monoclonal antibody cc49; monoclonal antibody cc49 i 125; monoclonal antibody chl6; monoclonal antibody chl6 gadoteric acid y 90; monoclonal antibody e4; monoclonal antibody e4 i 131; monoclonal antibody j591 bi 213; monoclonal antibody j591 gadoteric acid in 111; monoclonal antibody j591 gadoteric acid lu 177; monoclonal antibody j591 gadoteric acid y 90; monoclonal antibody j591 i 131; monoclonal antibody j591 in 111; monoclonal antibody j591 y 90; monoclonal antibody kc4; monoclonal antibody kc4 y 90 |
| Journal Title: | Quarterly Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 48 |
| Issue: | 4 |
| ISSN: | 1824-4785 |
| Publisher: | Edizioni Minerva Medica |
| Date Published: | 2004-12-01 |
| Start Page: | 297 |
| End Page: | 304 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 15640793 |
| DOI/URL: | |
| Notes: | Q. J. Nucl. Med. Mol. Imaging -- Cited By (since 1996):15 -- Export Date: 16 June 2014 -- CODEN: QJNMA C2 - 15640793 -- Source: Scopus |
